The Almagest | Long term gene therapy beneficial for advanced heart failure patients The Almagest (The Almagest) According to a research conducted at Icahn School of Medicine at Mount Sinai suggested that the long-term benefits of a single dose of the given gene therapy AAV1/SERCA2a in advanced heart failure patients is quite beneficial. This ... |
